Berkeley, CA and Vancouver, BC – May 31, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), announced today the establishment of its Scientific Advisory Board (SAB) engaging a number of highly-experienced leading experts in the field of immune-oncology. Briacell is an immuno-oncology focused biotechnology company with a proprietary vaccine, Briavax™, …
Berkeley, CA and Vancouver, BC – May 8, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company, today announced dosing of the first patient in BriaCell’s Phase I/IIa clinical trial evaluating the Company’s lead product candidate, BriaVax™, a genetically engineered whole-cell vaccine derived from a human …
The Wall Street Analyzer Interview with Dr. Williams – 2017
Consolidated Financial Statements For the Years Ended July 31, 2016 and 2015
BERKELEY, CA and VANCOUVER, BC–(Marketwired – March 24, 2017) – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce it has completed its previously announced non-brokered private placement financing (the “Offering”) of 5,612,083 units (the “Units”) for aggregate gross proceeds to the Company in the amount of $1,346,900 …
Berkeley, CA and Vancouver, BC – March 15, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, today announced that the U.S. Food and Drug Administration (FDA) has provided clearance to initiate an open-label Phase I/IIa clinical trial of BriaVaxTM in …
Berkeley, CA and Vancouver, BC – March 7, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) today announced that it has filed an international patent application under the Patent Cooperation Treaty (PCT) to further expand its intellectual property portfolio underlying the Company’s current and anticipated pipeline of whole-cell cancer vaccines, …
Berkeley, CA and Vancouver, BC – February 27, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) announced today that its President and CEO, Dr. William Williams has entered into a non-brokered private placement (the “Offering”) of 5,416,667 units of the Company (the “Units”) at a price of C$0.24 per Unit …
Berkeley, CA and Vancouver, BC – February 6, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), a clinical-stage company dedicated to the development of immuno-oncology treatments, today announced that the Company has submitted a Chemistry, Manufacturing, and Controls (CMC) amendment which includes the details of extensive testing performed on BriaVax™, …
Berkeley, CA and Vancouver, BC – January 5, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), a clinical-stage immuno-oncology company dedicated to the development of novel immuno-oncology therapeutics, today announced that Jason Napodano, senior equity analyst at BioNap Consulting, Inc., included BriaCell in the list of key players in immuno-oncology. …